Cancer Research Annual Meeting 2010 EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shinojima, N.
Right arrow Articles by Ushio, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shinojima, N.
Right arrow Articles by Ushio, Y.
[Cancer Research 63, 6962-6970, October 15, 2003]
© 2003 American Association for Cancer Research

Regular Articles

Prognostic Value of Epidermal Growth Factor Receptor in Patients with Glioblastoma Multiforme1

Naoki Shinojima2, Kenji Tada, Shoji Shiraishi, Takanori Kamiryo, Masato Kochi, Hideo Nakamura, Keishi Makino, Hideyuki Saya, Hirofumi Hirano, Jun-ichi Kuratsu, Koji Oka, Yasuji Ishimaru and Yukitaka Ushio

Departments of Neurosurgery [N. S., K. T., S. S., T. K., M. K., H. N., K. M., Y. U.] and Tumor Genetics and Biology [H. S.], Kumamoto University School of Medicine, Kumamoto 860-8556 and 860-0811; Neurosurgery, Kagoshima University School of Medicine, Kagoshima 890-8520 [H. H., J-i. K.]; Neurosurgery, Nakamura Memorial Hospital, Sapporo 060-8570 [K. O.]; and Division of Pathology, Kumamoto University College of Medical Science, Kumamoto 862-0976 [Y. I.], Japan

Glioblastoma multiforme (GBM) frequently involves amplification and alteration of the epidermal growth factor receptor (EGFR) gene, resulting in overexpression of varied mutations, including the most common mutation, EGFRvIII, as well as wild-type EGFR (EGFRwt). To test the prognostic value of EGFR, we retrospectively analyzed the relationship between treatment outcomes and the EGFR gene in 87 newly diagnosed adult patients with supratentorial GBM enrolled in clinical trials. The EGFR gene status was assessed by Southern blots and EGFR expression by immunohistochemistry using three monoclonal antibodies (EGFR.25 for EGFR, EGFR.113 for EGFRwt, and DH8.3 for EGFRvIII). EGFR amplification was detected in 40 (46%) of the 87 GBM patients; in 39 (97.5%) of these, EGFR was overexpressed. On the other hand, in 46 of 47 patients without EGFR amplification (97.9%), no EGFR overexpression was present. There was a close correlation between EGFR amplification and EGFR overexpression (P < 0.0001). EGFRwt was overexpressed in 27 of the 40 (67.5%) patients with, and in none without, EGFR amplification (P < 0.0001). Similarly, EGFRvIII was overexpressed in 18 (45.0%) of 40 patients with and in 4 (8.5%) of 47 patients without EGFR amplification (P < 0.0001). The finding that 8 (20%) of the patients with EGFR amplification/EGFR overexpression manifested overexpression of neither EGFRwt nor EGFRvIII indicates that they overexpressed other types of EGFR. Multivariate analysis demonstrated that EGFR amplification was an independent, significant, unfavorable predictor for overall survival (OS) in all patients (P = 0.038, HR = 1.67). With respect to the relationship of age to EGFR prognostication, the EGFR gene status was a more significant prognosticator in younger patients, particularly in those <60 years (P = 0.0003, HR = 3.15), whereas not so in older patients. EGFRvIII overexpression, on the other hand, was not predictive for OS. However, in patients with EGFR amplification, multivariate analysis revealed that EGFRvIII overexpression was an independent, significant, poor prognostic factor for OS (P = 0.0044, HR = 2.71). This finding indicates that EGFRvIII overexpression in the presence of EGFR amplification is the strongest indicator of a poor survival prognosis. In GBM patients, EGFR is of significant prognostic value for predicting survival, and the overexpression of EGFRvIII with amplification plays an important role in enhanced tumorigenicity.




This article has been cited by other articles:


Home page
 Mol. Cell. ProteomicsHome page
U. Rajcevic, K. Petersen, J. C. Knol, M. Loos, S. Bougnaud, O. Klychnikov, K. W. Li, T. V. Pham, J. Wang, H. Miletic, et al.
iTRAQ-based Proteomics Profiling Reveals Increased Metabolic Activity and Cellular Cross-talk in Angiogenic Compared with Invasive Glioblastoma Phenotype
Mol. Cell. Proteomics, November 1, 2009; 8(11): 2595 - 2612.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
E. P. Jane, D. R. Premkumar, S. O. Addo-Yobo, and I. F. Pollack
Abrogation of Mitogen-Activated Protein Kinase and Akt Signaling by Vandetanib Synergistically Potentiates Histone Deacetylase Inhibitor-Induced Apoptosis in Human Glioma Cells
J. Pharmacol. Exp. Ther., October 1, 2009; 331(1): 327 - 337.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
B. Neyns, J. Sadones, E. Joosens, F. Bouttens, L. Verbeke, J.-F. Baurain, L. D'Hondt, T. Strauven, C. Chaskis, P. In't Veld, et al.
Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma
Ann. Onc., September 1, 2009; 20(9): 1596 - 1603.
[Abstract] [Full Text] [PDF]

Home page
 Am J Clin PatholHome page
D. Mahajan and R. A. Prayson
Repeated Molecular Testing in Gliomas: A Retrospective Study of 53 Cases
Am J Clin Pathol, July 1, 2009; 132(1): 118 - 124.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
G. Karpel-Massler, U. Schmidt, A. Unterberg, and M.-E. Halatsch
Therapeutic Inhibition of the Epidermal Growth Factor Receptor in High-Grade Gliomas: Where Do We Stand?
Mol. Cancer Res., July 1, 2009; 7(7): 1000 - 1012.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
T. Okamura, S. Singh, J. Buolamwini, T. Haystead, H. Friedman, D. Bigner, and F. Ali-Osman
Tyrosine Phosphorylation of the Human Glutathione S-Transferase P1 by Epidermal Growth Factor Receptor
J. Biol. Chem., June 19, 2009; 284(25): 16979 - 16989.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J.-S. Guillamo, S. de Bouard, S. Valable, L. Marteau, P. Leuraud, Y. Marie, M.-F. Poupon, J.-J. Parienti, E. Raymond, and M. Peschanski
Molecular Mechanisms Underlying Effects of Epidermal Growth Factor Receptor Inhibition on Invasion, Proliferation, and Angiogenesis in Experimental Glioma
Clin. Cancer Res., June 1, 2009; 15(11): 3697 - 3704.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
Z. A. Kohutek, C. G. diPierro, G. T. Redpath, and I. M. Hussaini
ADAM-10-Mediated N-Cadherin Cleavage Is Protein Kinase C-{alpha} Dependent and Promotes Glioblastoma Cell Migration
J. Neurosci., April 8, 2009; 29(14): 4605 - 4615.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
C. M.-E. Sauvageot, J. L. Weatherbee, S. Kesari, S. E. Winters, J. Barnes, J. Dellagatta, N. R. Ramakrishna, C. D. Stiles, A. L.-J. Kung, M. W. Kieran, et al.
Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells
Neuro-oncol, January 1, 2009; 11(2): 109 - 121.
[Abstract] [Full Text] [PDF]

Home page
 J Child NeurolHome page
O. J. Becher, K. M. Peterson, S. Khatua, M. R. Santi, and T. J. MacDonald
IGFBP2 Is Overexpressed by Pediatric Malignant Astrocytomas and Induces the Repair Enzyme DNA-PK
J Child Neurol, October 1, 2008; 23(10): 1205 - 1213.
[Abstract] [PDF]

Home page
 Mol. Biol. CellHome page
H.-D. Kim, T. W. Guo, A. P. Wu, A. Wells, F. B. Gertler, and D. A. Lauffenburger
Epidermal Growth Factor-induced Enhancement of Glioblastoma Cell Migration in 3D Arises from an Intrinsic Increase in Speed But an Extrinsic Matrix- and Proteolysis-dependent Increase in Persistence
Mol. Biol. Cell, October 1, 2008; 19(10): 4249 - 4259.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Radiol.Home page
C M West, L Joseph, and S Bhana
Epidermal growth factor receptor-targeted therapy
Br. J. Radiol., October 1, 2008; 81(Special_Issue_1): S36 - S44.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
W. P. Mason and J. G. Cairncross
Invited Article: The expanding impact of molecular biology on the diagnosis and treatment of gliomas
Neurology, July 29, 2008; 71(5): 365 - 373.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. A. Brandes, E. Franceschi, A. Tosoni, M. E. Hegi, and R. Stupp
Epidermal Growth Factor Receptor Inhibitors in Neuro-oncology: Hopes and Disappointments
Clin. Cancer Res., February 15, 2008; 14(4): 957 - 960.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Schlomm, P. Kirstein, L. Iwers, B. Daniel, T. Steuber, J. Walz, F. H.K. Chun, A. Haese, J. Kollermann, M. Graefen, et al.
Clinical Significance of Epidermal Growth Factor Receptor Protein Overexpression and Gene Copy Number Gains in Prostate Cancer
Clin. Cancer Res., November 15, 2007; 13(22): 6579 - 6584.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. M.P. Omuro, S. Faivre, and E. Raymond
Lessons learned in the development of targeted therapy for malignant gliomas
Mol. Cancer Ther., July 1, 2007; 6(7): 1909 - 1919.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. A. Barnett, D. L. Urbauer, G. I. Murray, G. N. Fuller, and A. B. Heimberger
Cytochrome P450 1B1 Expression in Glial Cell Tumors: An Immunotherapeutic Target
Clin. Cancer Res., June 15, 2007; 13(12): 3559 - 3567.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. E. Pelloski, K. V. Ballman, A. F. Furth, L. Zhang, E. Lin, E. P. Sulman, K. Bhat, J. M. McDonald, W.K. A. Yung, H. Colman, et al.
Epidermal Growth Factor Receptor Variant III Status Defines Clinically Distinct Subtypes of Glioblastoma
J. Clin. Oncol., June 1, 2007; 25(16): 2288 - 2294.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. C. Sok, F. M. Coppelli, S. M. Thomas, M. N. Lango, S. Xi, J. L. Hunt, M. L. Freilino, M. W. Graner, C. J. Wikstrand, D. D. Bigner, et al.
Mutant Epidermal Growth Factor Receptor (EGFRvIII) Contributes to Head and Neck Cancer Growth and Resistance to EGFR Targeting
Clin. Cancer Res., September 1, 2006; 12(17): 5064 - 5073.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Q. Wei, L. Clarke, D. K. Scheidenhelm, B. Qian, A. Tong, N. Sabha, Z. Karim, N. A. Bock, R. Reti, R. Swoboda, et al.
High-grade glioma formation results from postnatal pten loss or mutant epidermal growth factor receptor expression in a transgenic mouse glioma model.
Cancer Res., August 1, 2006; 66(15): 7429 - 7437.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
H. Ji, X. Zhao, Y. Yuza, T. Shimamura, D. Li, A. Protopopov, B. L. Jung, K. McNamara, H. Xia, K. A. Glatt, et al.
Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors
PNAS, May 16, 2006; 103(20): 7817 - 7822.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. B. Ramnarain, S. Park, D. Y. Lee, K. J. Hatanpaa, S. O. Scoggin, H. Otu, T. A. Libermann, J. M. Raisanen, R. Ashfaq, E. T. Wong, et al.
Differential Gene Expression Analysis Reveals Generation of an Autocrine Loop by a Mutant Epidermal Growth Factor Receptor in Glioma Cells
Cancer Res., January 15, 2006; 66(2): 867 - 874.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Aghi, P. Gaviani, J. W. Henson, T. T. Batchelor, D. N. Louis, and F. G. Barker II
Magnetic Resonance Imaging Characteristics Predict Epidermal Growth Factor Receptor Amplification Status in Glioblastoma
Clin. Cancer Res., December 15, 2005; 11(24): 8600 - 8605.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Van Schaeybroeck, A. Karaiskou-McCaul, D. Kelly, D. Longley, L. Galligan, E. Van Cutsem, and P. Johnston
Epidermal Growth Factor Receptor Activity Determines Response of Colorectal Cancer Cells to Gefitinib Alone and in Combination with Chemotherapy
Clin. Cancer Res., October 15, 2005; 11(20): 7480 - 7489.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
Y.-H. Zhou, K. R. Hess, L. Liu, Mark. E. Linskey, and W.K. A. Yung
Modeling prognosis for patients with malignant astrocytic gliomas: Quantifying the expression of multiple genetic markers and clinical variables
Neuro-oncol, October 1, 2005; 7(4): 485 - 494.
[Abstract] [PDF]

Home page
 Clin. Cancer Res.Home page
V. Damiano, D. Melisi, C. Bianco, D. Raben, R. Caputo, G. Fontanini, R. Bianco, A. Ryan, A. R. Bianco, S. De Placido, et al.
Cooperative Antitumor Effect of Multitargeted Kinase Inhibitor ZD6474 and Ionizing Radiation in Glioblastoma
Clin. Cancer Res., August 1, 2005; 11(15): 5639 - 5644.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. B. Heimberger, R. Hlatky, D. Suki, D. Yang, J. Weinberg, M. Gilbert, R. Sawaya, and K. Aldape
Prognostic Effect of Epidermal Growth Factor Receptor and EGFRvIII in Glioblastoma Multiforme Patients
Clin. Cancer Res., February 15, 2005; 11(4): 1462 - 1466.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Blum, J. Jacob-Hirsch, N. Amariglio, G. Rechavi, and Y. Kloog
Ras Inhibition in Glioblastoma Down-regulates Hypoxia-Inducible Factor-1{alpha}, Causing Glycolysis Shutdown and Cell Death
Cancer Res., February 1, 2005; 65(3): 999 - 1006.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. B. Heimberger, E. C. McGary, D. Suki, M. Ruiz, H. Wang, G. N. Fuller, and M. Bar-Eli
Loss of the AP-2{alpha} Transcription Factor Is Associated with the Grade of Human Gliomas
Clin. Cancer Res., January 1, 2005; 11(1): 267 - 272.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
Y. Nakahara, T. Shiraishi, H. Okamoto, T. Mineta, T. Oishi, K. Sasaki, and K. Tabuchi
Detrended fluctuation analysis of genome-wide copy number profiles of glioblastomas using array-based comparative genomic hybridization
Neuro-oncol, October 1, 2004; 6(4): 281 - 289.
[Abstract] [PDF]

Home page
 Cancer Res.Home page
H. Ohgaki, P. Dessen, B. Jourde, S. Horstmann, T. Nishikawa, P.-L. Di Patre, C. Burkhard, D. Schuler, N. M. Probst-Hensch, P. C. Maiorka, et al.
Genetic Pathways to Glioblastoma: A Population-Based Study
Cancer Res., October 1, 2004; 64(19): 6892 - 6899.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. P. Steinbach, A. Klumpp, H. Wolburg, and M. Weller
Inhibition of Epidermal Growth Factor Receptor Signaling Protects Human Malignant Glioma Cells from Hypoxia-Induced Cell Death
Cancer Res., March 1, 2004; 64(5): 1575 - 1578.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.